Drugs / Lopinavir/Ritonavir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00573001 | Jul 2008 → Jul 2011 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2012-03-06 | Merck Sharp & Dohme LLC | Results Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 merck.com ↗
In this study, concomitant administration of VICTRELIS with ritonavir (Norvir ® ) in combination with atazanavir (Reyataz ® ) or darunavir (Prezista ® ), or with lopinavir/ritonavir (Kaletra ® ) resulted in reduced exposures of the HIV medicines and VICTRELIS. |
| 2012-02-08 | Merck Sharp & Dohme LLC | Results Merck Informs U.S. Physicians of Results of Drug Interaction Study of Co-Administration of VICTRELIS™ with Ritonavir-Boosted HIV Protease Inhibitors merck.com ↗
In this study, concomitant administration of VICTRELIS with ritonavir (Norvir®) in combination with atazanavir (Reyataz®) or darunavir (Prezista®),or with lopinavir/ritonavir (Kaletra®) resulted in reduced exposures of the HIV medicines and VICTRELIS. |
All press releases naming this drug 2 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lopinavir/Ritonavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00573001 ↗ |